Early Evidence of Impact of Monovalent Rotavirus Vaccine in Togo

18Citations
Citations of this article
41Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Togo introduced monovalent rotavirus vaccine starting 19 June 2014. We compared all-cause acute gastroenteritis (AGE) hospitalizations and rotavirus-associated hospitalizations during the prevaccine period (July 2008-June 2014) to 1 year after vaccine introduction (July 2014-June 2015). The proportion of children with AGE who tested positive for rotavirus declined from 53% (645/1223) in prevaccine years to 36% (68/187) in the postvaccine year (P <1 year of age who were eligible for vaccination and was greatest during the rotavirus season months, supporting that it was associated with vaccine implementation.

Cite

CITATION STYLE

APA

Tsolenyanu, E., Mwenda, J. M., Dagnra, A., Leshem, E., Godonou, M., Nassoury, I., … Parashar, U. D. (2016). Early Evidence of Impact of Monovalent Rotavirus Vaccine in Togo. Clinical Infectious Diseases, 62, S196–S199. https://doi.org/10.1093/cid/civ1182

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free